Company profile

Ticker
MRK
Exchange
Website
CEO
Kenneth C. Frazier
Employees
Incorporated
Location
Fiscal year end
Former names
Merck & Co. Inc., SCHERING PLOUGH CORP
SEC CIK
IRS number
221918501

MRK stock data

(
)

Calendar

5 Aug 20
7 Aug 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Jun 20 Mar 20 Dec 19 Sep 19
Revenue 10.87B 12.06B 11.87B 12.4B
Net income 3.01B 3.22B 2.36B 1.91B
Diluted EPS 1.18 1.26 0.92 0.74
Net profit margin 27.69% 26.70% 19.91% 15.38%
Net change in cash 3.68B -2.25B 1.81B 1.21B
Cash on hand 11.1B 7.43B 9.68B 7.87B
Cost of revenue 3.16B 3.31B 3.67B 3.99B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 46.84B 42.29B 40.12B 39.81B
Net income 9.78B 6.19B 2.42B 3.94B
Diluted EPS 3.81 2.32 0.87 1.41
Net profit margin 20.87% 14.64% 6.03% 9.90%
Net change in cash 1.71B 1.87B -423M -2.01B
Cash on hand 9.68B 7.97B 6.09B 6.52B
Cost of revenue 14.11B 13.51B 12.91B 14.03B

Financial data from Merck & Co. earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
5 Aug 20 Frank Clyburn Common Stock Sell Dispose S No 81.5466 18,876 1.54M 80,763.106
5 Aug 20 Frank Clyburn Common Stock Option exercise Aquire M No 0 18,876 0 99,639.106
5 Aug 20 Frank Clyburn Stock Option Common Stock Option exercise Dispose M No 39.29 18,876 741.64K 0
17 Jul 20 Julie L. Gerberding Common Stock Sell Dispose S Yes 80.0097 18,174 1.45M 26,577.138
17 Jul 20 Julie L. Gerberding Common Stock Sell Dispose S Yes 80 18,111 1.45M 44,751.138
17 Jul 20 Julie L. Gerberding Common Stock Option exercise Aquire M No 0 18,111 0 62,862.138
17 Jul 20 Julie L. Gerberding Stock Option Common Stock Option exercise Dispose M No 54.68 18,111 990.31K 0
30 Jun 20 Coe Mary Ellen Phantom Stock Common Stock Grant Aquire A No 77.33 420.277 32.5K 6,963.921
30 Jun 20 Christine E Seidman Phantom Stock Common Stock Grant Aquire A No 77.33 210.138 16.25K 2,837.977
30 Jun 20 Wendell Peter C Phantom Stock Common Stock Grant Aquire A No 77.33 387.948 30K 97,156.527
73.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2302 2358 -2.4%
Opened positions 137 307 -55.4%
Closed positions 193 104 +85.6%
Increased positions 1026 936 +9.6%
Reduced positions 901 856 +5.3%
13F shares
Current Prev Q Change
Total value 143.29B 174.42B -17.8%
Total shares 1.86B 1.91B -2.5%
Total puts 14.65M 18.37M -20.2%
Total calls 14.87M 16.01M -7.1%
Total put/call ratio 1.0 1.1 -14.1%
Largest owners
Shares Value Change
Vanguard 217M $16.7B +3.1%
BLK BlackRock 196.35M $15.11B +2.9%
STT State Street 117.34M $9.1B +0.7%
Wellington Management 47.87M $3.68B -15.5%
BAC Bank of America 46.06M $3.54B +8.8%
Geode Capital Management 39.88M $3.06B -0.3%
Capital World Investors 38.21M $2.94B -38.2%
BK Bank of New York Mellon 34.82M $2.68B +0.1%
NTRS Northern Trust 32.9M $2.53B +2.5%
JPM JPMorgan Chase & Co. 30.92M $2.38B -10.8%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -27.53M EXIT
Capital World Investors 38.21M -23.58M -38.2%
Capital International Investors 27.87M -11.76M -29.7%
Wellington Management 47.87M -8.79M -15.5%
Massachusetts Financial Services 16.74M +6.7M +66.8%
Vanguard 217M +6.45M +3.1%
BLK BlackRock 196.35M +5.56M +2.9%
JPM JPMorgan Chase & Co. 30.92M -3.75M -10.8%
AMP Ameriprise Financial 21.88M +3.74M +20.6%
BAC Bank of America 46.06M +3.71M +8.8%

Financial report summary

?
Risks
  • The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.
  • As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.
  • Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company’s results of operations and financial condition.
  • The Company’s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that have lost patent protection.
  • The Company’s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.
  • The Company’s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.
  • Developments following regulatory approval may adversely affect sales of the Company’s products.
  • The Company faces intense competition from lower cost generic products.
  • The Company faces intense competition from competitors’ products.
  • The Company faces continued pricing pressure with respect to its products.
  • The health care industry in the United States has been, and will continue to be, subject to increasing regulation and political action.
  • The Company is increasingly dependent on sophisticated software applications and computing infrastructure. In 2017, the Company experienced a network cyber-attack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. The Company could be a target of future cyber-attacks.
  • The uncertainty in global economic conditions together with cost-reduction measures being taken by certain governments could negatively affect the Company’s operating results.
  • The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company’s results of operations and financial condition.
  • Failure to attract and retain highly qualified personnel could affect the Company’s ability to successfully develop and commercialize products.
  • In the past, the Company has experienced difficulties and delays in manufacturing certain of its products, including vaccines.
  • The Company may not be able to realize the expected benefits of its investments in emerging markets.
  • The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
  • The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
  • Pharmaceutical products can develop unexpected safety or efficacy concerns.
  • Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business.
  • Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.
  • Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company’s future results of operations and financial condition.
  • Product liability insurance for products may be limited, cost prohibitive or unavailable.
  • The proposed Spin-Off of NewCo may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.
  • The costs to complete the proposed Spin-Off will be significant. In addition, the Company may be unable to achieve some or all of the strategic and financial benefits that it expects to achieve from the Spin-Off of NewCo.
  • Following the Spin-Off, the price of shares of the Company’s common stock may fluctuate significantly.
  • There could be significant income tax liability if the Spin-Off or certain related transactions are determined to be taxable for U.S. federal income tax purposes.
  • Cautionary Factors that May Affect Future Results
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accessible, adsorbed, advantage, affordable, Ahead, allogenic, alpha, anogenital, Assistant, background, BARDA, Bio, Biomedical, Bioscience, biotechnology, BV, ccRCC, challenged, characterized, checkpoint, cisplatin, clear, CMV, committed, composed, concomitantly, concurrent, Conference, conjugate, coupled, criteria, CRL, dampening, dedicated, developmental, dimeglumine, Dr, elicited, engineered, epithelial, Flavor, fosaprepitant, GmbH, Greater, growing, healthy, hematology, hematopoietic, highly, IAVI, immunocompromised, immunogenicity, influenza, innovative, intramuscular, islatravir, ISPPD, joinder, JPN, Justice, Labor, laboratory, lag, library, licensure, lieu, low, memorandum, Ministry, Moderna, month, NGM, nonmetastatic, nonprofit, NRTTI, nucleoside, oropharyngeal, Pasteur, people, platform, Pneumococci, PRC, preclinical, procedure, randomized, reached, recovery, Reddy, repeated, Ridgeback, RNA, rVSV, SAR, Science, Secretary, Sentinel, Silgard, sNDA, Spectrum, stem, storage, stream, subdermal, Sun, switched, Symposium, technology, temperature, tolerability, transcriptase, translocation, transplant, unchallenged, underway, unmet, untreated, urgent, vector, vesicular, VHL, viral, Virbac, von, Week, Welfare, withdrawn
Removed: Afferent, aprepitant, beginning, buying, drove, glargine, insulin, making, obtained, proceeding, submitted, subpoena